24 October 2024
Active participation of VIVEbiotech at the ESGCT´s 31st annual meeting
The European Society of Gene and Cell Therapy´s annual congress is in full swing.
Expertise in virology, we adapt ad-hoc to meet the specific requirements of your lentiviral vector.
Business model
GMP CDMO focused on different stages of the process.
Specialization
We work exclusively in lentivirus, offering comprehensive services.
Customized service
Technical adaptation and timely slot availability for each project.
Quality and safety
Compliance with EMA and FDA regulatory requirements.
Trusted by industry leaders
Vivebiotech in data
+45 customers
in the US, Europe, Asia and Australia
4x greater batch capacity
in reactor since 2020
4x increase in staff
since 2018
7 rooms dedicated
exclusively to lentivirus production
70% hold PhDs or bachelor's degrees
combining young talent and experience
About us
We are a Contract Development and Manufacturing Organization (CDMO) with over 40 biotech companies worldwide that have placed their trust in us.
Read moreOur value
VIVEbiotech is one of the only companies in the world specialized exclusively in lentiviral vectors. One of the things that sets us apart is our expertise not only in production but also virology, backed by a team of professionals with more than 30 years of experience.
Read more
See all news
Last news
8 October 2024
VIVEbiotech participates in Cell & Gene Meeting on the Mesa
As in several past editions, VIVEbiotech is participating in Cell & Gene Meeting on the Mesa.
With the support of
